Vanda Pharmaceuticals Awaits Critical FDA Decision Amid Mixed Financial Performance

Vanda Pharmaceuticals (VNDA) is entering a pivotal week as it awaits a high-stakes regulatory decision from the FDA regarding its drug, Bysanti. This PDUFA deadline comes on the heels of weak financial results for the 2025 fiscal year, where the company reported a significant miss in GAAP earnings per share and substantial losses. Despite these bottom-line struggles, revenue grew by 9%, largely supported by the steady sales performance of its Fanapt medication. Investors are closely watching the upcoming regulatory outcome, which is viewed as a binary catalyst that could either trigger a sharp recovery or further pressure the stock. Currently, VNDA shares are trading at a deep valuation discount of approximately 0.5x enterprise value to sales (EV/sales). The combination of regulatory uncertainty and depressed valuation makes the stock a high-risk, high-reward play for biotech investors this week.